{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-097534","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.926187+00:00","generated_at":"2026-05-15T18:14:15.086967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"enGene Q1 net loss $29.8M; cash $312.5M; LEGEND data update at spring 2026 conference","bullets":["Net loss $29.8M ($0.44/share) vs $24.6M ($0.48/share) year ago; operating expenses $31.2M.","Cash & marketable securities $312.5M; expected runway into 2H 2028.","Expanded Hercules Capital debt facility to $125M for detalimogene development & commercial prep.","LEGEND pivotal cohort 63% CR at any time (n=62); BLA filing planned for 2H 2026.","12-month CR data expected 2H 2026; CDRP program selected by FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-097534","json":"https://secwatch.observer/filing/0001193125-26-097534.json","markdown":"https://secwatch.observer/filing/0001193125-26-097534.md","text":"https://secwatch.observer/filing/0001193125-26-097534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526097534/0001193125-26-097534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526097534/engn-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:14:15.086967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9facbe5ba7acc79bab49118f8cf1f2191b93c1ef","claim":"enGene Therapeutics Inc. reported first quarter ended January 31, 2026 results: net income net loss attributable to common shareholders was approximately $29.8 million, EPS $0.44 per share.","evidence_excerpt":"enGene Reports First Quarter 2026 Financial Results and Provides Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526097534/0001193125-26-097534-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended January 31, 2026"},{"label":"Net income","value":"net loss attributable to common shareholders was approximately $29.8 million"},{"label":"EPS","value":"$0.44 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}